Nedaplatin and 5-FU combined with radiation in the treatment for esophageal cancer.
Nedaplatin and 5-FU combined with radiation in the treatment for esophageal cancer.
复制标题
奈达铂和5-FU联合放射治疗食管癌。
DOI：
10.1007/bf03217851
复制
发表时间：
1998
期刊：
影响因子：
--
通讯作者：
K. Hioki
中科院分区：
文献类型：
--
作者：
H. Yamanaka;T. Motohiro;T. Michiura;A. Asai;T. Mori;K. Hioki
本文报道了一系列食管癌患者采用新型抗肿瘤铂制剂奈达铂（Nedaplatin）加5-FU（5-FU）联合放射治疗的临床疗效、副作用及并发症。有2例患者完全缓解，11例患者部分缓解，因此缓解率为76.5%。主要不良反应为血液学毒性，包括白细胞减少症（13例，76.5%）、血小板减少症（8例，47.1%）和血清血红蛋白浓度降低（9例，52.9%）。白细胞减少症和血小板减少症，虽然分别有3例和2例患者的严重程度为3级，但在所有受影响病例中均自发消退。胃肠道不良反应轻微，包括7例患者（41.2%）食欲不振和2例患者（11.8%）恶心。观察到的唯一肾功能异常是1例患者的血清肌酐轻微升高。奈达铂和5-FU联合化疗加放射治疗食管癌的反应率高，胃肠道和肾脏毒性降低。结果表明，奈达铂的联合治疗是临床上有用的。
A series of patients with esophageal cancer was treated with chemotherapeutic regimens of the new antitumor platinum preparation nedaplatin plus 5-FU in combination with radiation therapy, and the therapeutic responses, side effects, and complications were clinically assessed. There were 2 patients with a complete response and 11 patients with a partial response, hence, a response rate of 76.5%. Major adverse reactions were those of hematological toxicity and included leukopenia (13 patients, 76.5%), thrombocytopenia (8 patients, 47.1%), and lowered serum hemoglobin concentration (9 patients, 52.9%). The leukopenia and thrombocytopenia, though of a grade 3 severity in 3 and 2 patients, respectively, subsided spontaneously in all affected cases. Gastrointestinal adverse reactions were mild and included appetite loss in 7 patients (41.2%) and nausea in 2 patients (11.8%). The only abnormality in renal function observed was a slight elevation of serum creatinine in one patient. The combined therapy of chemotherapy with nedaplatin and 5-FU plus radiation produced a high response rate in the treatment of carcinoma of the esophagus and was associated with reduced gastrointestinal and renal toxicity. The results indicate the combined therapy with nedaplatin to be clinically useful.
影响因子：
158.5
作者：
HERSKOVIC, A;MARTZ, K;EMAMI, B
通讯作者：
EMAMI, B